Skip to main navigation Skip to search Skip to main content

Polypharmacy in cardiorenal syndrome patients

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Cardiorenal syndrome (CRS) is a term defined as complex interactions between concomitant cardiac and renal dysfunction in which disease of one organ initiates, perpetuates, and/or accelerates the decline in the other. It accounts for a third of presentations with heart failure and is associated with poor clinical outcomes. Polypharmacy (defined as using five or more medications) is common in CRS patients and is associated with worst clinical outcomes. The risk for polypharmacy increases to several fold with associated comorbidities, poses risks to the overall health of the patient, and enhances non-compliance to essential medications. Deprescribing non-essential medications, coordination between multiple specialties to mitigate the risk of polypharmacy, pharmacist- and nurse-led clinics to improve adherence to medications, use of polypills and telemonitoring are various methods to reduce polypharmacy. In this paper, we highlight different strategies to prevent polypharmacy and improve compliance and adherence to essential medications.

Original languageEnglish
Pages (from-to)141-148
Number of pages8
JournalClinical Nephrology
Volume99
Issue number3
DOIs
StatePublished - Mar 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • cardio-renal-metabolic
  • cardiorenal syndrome
  • chronic kidney disease
  • polypharmacy

Fingerprint

Dive into the research topics of 'Polypharmacy in cardiorenal syndrome patients'. Together they form a unique fingerprint.

Cite this